EUVIMEDEUVIMED entdecken
Leitlinie

Abstract 17151: Novel Guideline-Directed Medical Therapy and Ventricular Arrhythmia Risk in Diabetes with Non-Ischemic Cardiomyopathy

Abstract 17151: Neue leitliniengerechte medikamentöse Therapie und Risiko ventrikulärer Arrhythmien bei Diabetes mit nichtischämischer Kardiomyopathie

Daniel Han, Edwin K Heist, Marye Gleva, Ilan Goldenberg, Scott McNitt, Mary Brown, Luigi Di Biase, Karthik Venkatesh Prasad, David Frazier, Jonathan W Dukes, Jeanne E Poole, Valentina S Kutyifa

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.17151 ↗

Auf einen Blick

Bei 1.000 Patient:innen mit nichtischämischer Kardiomyopathie war SGLT2i bei Diabetes mit selteneren VT/VF verbunden. ARNI war bei Diabetes mit geringerem Sterberisiko verbunden.

Fragestellung

Wie hängen Diabetes und neue GDMT mit dem Risiko für VT/VF oder Tod bei NICM-Patient:innen mit ICD oder CRT-D zusammen?

Methode

Analyse von 1.000 BIO-LIBRA-Patient:innen mit ICD oder CRT-D; 336 (34 %) mit Diabetes. Kaplan-Meier-Analysen und multivariate Cox-Analysen nach SGLT2i- oder ARNI-Gebrauch.

Ergebnisse

Bei Diabetes: SGLT2i 3 % vs. 10 % VT/VF, log-rank p=0,023; HR 0,20 (CI 0,03–1,50; p=0,12). ARNI 8 % vs. 17 % Tod, log-rank p=0,03; HR 0,58 (CI 0,36–0,94; p=0,025).

Schlussfolgerung der Autor:innen

Bei NICM war SGLT2i mit einer niedrigeren VT/VF-Rate verbunden, ARNI bei Diabetes mit einem signifikant niedrigeren Sterberisiko. Die Autor:innen betonen die Bedeutung beider Medikamente vor ICD- oder CRT-D-Implantation.

Kernaussagen

  • 1000 Patient:innen aus BIO-LIBRA, 336 mit Diabetes
  • SGLT2i bei Diabetes: 3 % vs. 10 % VT/VF
  • ARNI bei Diabetes: 8 % vs. 17 % Tod; HR 0,58

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Leitlinie in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Daniel Han und 11 weiteren Autor:innen.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy (BIO-LIBRA) study studied contemporary outcomes implantable cardioverter defibrillators (ICD) or cardiac resynchronization therapy (CRT-D) in non-ischemic cardiomyopathy (NICM) patients with guideline-directed medical therapy (GDMT) including SGLT2 inhibitor (SGLT2i) and ARNI. However, the risk of ventricular arrhythmias (VT/VF) was not assessed by diabetes and novel GDMT.

Objective

We aimed to examine the risk of VT/VF/Death by diabetes and novel GDMTs in NICM patients with ICD or CRT-D.

Methods

We included 1000 patients from BIO-LIBRA, enrolling 336 (34%) patients with diabetes, further stratified by SGLT2i or ARNI use. Rates of VT/VF and death alone were assessed by Kaplan-Meier analyses. Multivariate Cox-proportional analyses were performed to assess the risk of the primary endpoint of VT/VF or death alone by diabetes and by novel GDMTs.

Results

Patients with diabetes prescribed SGLT2i had the lowest rate of VT/VF compared to no SGLT2i (Figure A, 3% vs. 10%, log-rank p=0.023), linked to an 80% lower risk of VT/VF (HR=0.20, CI=0.03-1.50, p=0.12). Patients without diabetes had similar rates and risk of VT/VF with or without SGLT2i (Fig. A, HR=1.00, CI=0.14-7.43). Patients with diabetes and ARNI had a lower rate of death compared to no ARNI (Figure B, 8% vs. 17%, log-rank p=0.03) with a significant, 54% lower risk of death (HR=0.58, CI:0.36-0.94, p=0.025). Patients without diabetes had similar rates and risk of Death with or without ARNI as patients with diabetes and ARNI. Similar findings were found for VT/VF/death, but not for VT/VF only in patients with ARNI.

Conclusion

Among NICM patients, the use of novel GDMT, SGLT2i was linked to a lower rate of VT/VF, while the use of ARNI was linked to a significantly lower risk of death in patients with diabetes, highlighting the importance of incorporating these new medications into their treatment regimen prior to an ICD or CRT-D implantation to improve outcomes.

Zitieren

APA

Han, D., Heist, E. K., Gleva, M., Goldenberg, I., McNitt, S., Brown, M., Biase, L. D., Prasad, K. V., Frazier, D., Dukes, J. W., Poole, J. E., & Kutyifa, V. S. (2026). Abstract 17151: Novel Guideline-Directed Medical Therapy and Ventricular Arrhythmia Risk in Diabetes with Non-Ischemic Cardiomyopathy. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.17151

Vancouver

Han D, Heist EK, Gleva M, Goldenberg I, McNitt S, Brown M, et al. Abstract 17151: Novel Guideline-Directed Medical Therapy and Ventricular Arrhythmia Risk in Diabetes with Non-Ischemic Cardiomyopathy. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.17151

BibTeX
@article{Han2026,
  author = {Han, Daniel and Heist, Edwin K and Gleva, Marye and Goldenberg, Ilan and McNitt, Scott and Brown, Mary and Biase, Luigi Di and Prasad, Karthik Venkatesh and Frazier, David and Dukes, Jonathan W and Poole, Jeanne E and Kutyifa, Valentina S},
  title = {Abstract 17151: Novel Guideline-Directed Medical Therapy and Ventricular Arrhythmia Risk in Diabetes with Non-Ischemic Cardiomyopathy},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.17151}
}
Kostenlos starten →